Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 17Plasma cell 5Gastrointestinal 3Other hematologic neoplasm 2Myeloid 2Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Myeloproliferative Disorders 2Venous Thromboembolism 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × apixaban × Myeloid × Clear all
NCT04243122 2024-05-29

AIRPORT-MPN

Ottawa Hospital Research Institute

Phase 2 Completed
44 enrolled
Classical hematologyMyeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Completed
442 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡